Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198

Benzinga Newsdesk www.benzinga.com Negative 82.6%

Neg 82.6% Neu 0% Pos 0%

Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.